Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesDavid T. Rubin, Patrick Chamouard, Shadi Yarandi et al.|The Lancet|2024Cited by 95
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trialBrian G. Feagan, Dermot McGovern, Bruce E Sands et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 28